Device Trial Radar · NCT05547347
Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
15
Planned (sponsor's estimate)
Start
Mar 21, 2023
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 21, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I study assesses the safety, ultrasound visibility (conspicuity), and movement from normal position (migration) of the twinkling marker in patients with breast cancer that has spread to the axillary lymph nodes (locally advanced) who will be undergoing neoadjuvant systemic therapy and surgery. Biopsy markers are used to identify the sites of cancer involvement in both the breasts and lymph nodes. These biopsy markers are needed to help guide breast cancer surgery. Twinkling markers are designed to have the same size and shape of conventional biopsy markers, but are made of a radio-opaque material that assists with localization of the marker. The twinkling marker may make it more easily seen with ultrasound at the time of breast cancer surgery as compared to conventional biopsy markers.
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Locally Advanced Breast Carcinoma
- Resectable Breast Carcinoma
Interventions
Magnetic Resonance ImagingProcedure
Undergo MRI
MammogramProcedure
Undergo a mammogram
UltrasoundProcedure
Undergo a breast ultrasound
Ultrasound-Guided BiopsyProcedure
Undergo a percutaneous ultrasound-guided breast clip placement
Twinkle markerDevice
Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker on study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term efficacy of the twinkling markerTime frame: through study completion, an average of 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.